Almost 50,000 patients will be tested for a novel blood thinner by Bristol Myers Squibb and Johnson & Johnson

With ambitions to enroll close to 50,000 patients, Bristol Myers Squibb and Johnson & Johnson have started a series of big studies investigating a closely watched new blood-thinning medication. To investigate the effects of milvexian in patients who have experienced a stroke, acute coronary syndrome, or atrial fibrillation, the so-called Librexia trials will be divided into three phases. The stroke trial has already enrolled its first patient, and by July, the other two are anticipated to begin.

A new class of drugs termed Factor XIa inhibitors, which includes Milvexian, is created to compete favorably on safety with established market leaders like Xarelto and Eliquis. According to Bristol Myers Squibb, its testing strategies will provide the “most complete and unmatched” data collection in the drug’s class. Even most vaccination studies, which are typically the largest trials in pharmaceutical research, pale in comparison to the scope of the Librexia initiative. Also, it outperforms Bayer’s intentions, which were announced last month, to research asundexian, a competing therapy, in 27,000 patients.

Each business estimates that sales may reach $5 billion and that they may have potential top sellers on their hands. The drug Eliquis, created by Bristol-Myers Squibb and Pfizer, generated close to $12 billion in sales in 2017. In 2022, Xarelto’s distributors Bayer and J&J, who distribute the drug in several territories, reported combined sales of more than $7 billion. The potential of the new class of medications hinges on its ability to minimize internal bleeding risk, prevent strokes and other cardiac events, and complement current treatments. Despite conflicting results from earlier testing, Bristol Myers Squibb  and Bayer both pressed through with Phase 3 trials.

The businesses are likewise pressed for time. This decade will see the end of patent protection for Eliquis and Xarelto, opening the door to less expensive generic alternatives. Even if the businesses’ new class of medications receives regulatory approval, doctors might be reluctant to prescribe them if they cannot demonstrate a major safety benefit.

More about Bristol Myers Squibb

Bristol Myers Squibb (BMS) is a global biopharmaceutical company that specializes in the development of innovative medicines for the treatment of serious diseases, including cancer, cardiovascular disease, autoimmune disorders, and more. The company was formed in 1989 as a result of a merger between Bristol-Myers Company and Squibb Corporation. Bristol Myers Squibb (BMS) is headquartered in New York City and has operations in over 60 countries worldwide. The company employs more than 30,000 people globally and has a portfolio of over 30 marketed products. Some of Bristol Myers Squibb (BMS)‘s most well-known products include Opdivo, Eliquis, Orencia, and Yervoy.

BMS is committed to advancing scientific research and collaborating with healthcare providers, patients, and advocacy groups to improve patient outcomes. The company invests heavily in research and development, with a focus on discovering new treatments for unmet medical needs. BMS is also dedicated to sustainability and corporate responsibility, with a focus on reducing its environmental impact and supporting the communities in which it operates.

More about Johnson & Johnson (J&J)

Johnson & Johnson is a global healthcare company that operates in three main business segments: pharmaceuticals, medical devices, and consumer health products. The company was founded in 1886 and is headquartered in New Brunswick, New Jersey. Johnson & Johnson pharmaceutical division is focused on developing and commercializing drugs for a wide range of diseases and conditions, including cancer, immunological disorders, infectious diseases, and more. The medical devices division produces a wide range of products used in surgeries, orthopedics, cardiovascular disease, and more. Johnson & Johnson consumer health division produces a variety of over-the-counter products, including baby care, skin care, oral care, and women’s health products.

Johnson & Johnson is committed to innovation and invests heavily in research and development, with a focus on discovering new treatments and therapies for unmet medical needs. The company also emphasizes corporate social responsibility and sustainability, with a focus on reducing its environmental impact and improving the health and well-being of people around the world. In recent years, Johnson & Johnson  has faced legal challenges related to its talcum powder products, which have been linked to ovarian cancer and mesothelioma. The company has also been involved in litigation related to its role in the opioid epidemic in the United States. However, Johnson & Johnson has taken steps to address these issues and remains one of the largest and most respected healthcare companies in the world.

About Publisher

IR Research Publication is Publisher, Editorial, and Profile Building Service Provider. It Covers the Publication of Multiple Reputed Journals in the field of Biological, Medical, Pharmaceutical, and Life Sciences. IR Research Publication provides news on CDSCO decisions and FDA decisions, pharmaceutical industries, generic drugs, patents, and other pharma news.
For more details visit the link- https://irrespub.com/


Leave a Reply

Your email address will not be published. Required fields are marked *


Enjoy this blog? Please spread the word :)

Follow by Email